Gopalan Nair Rajesh1, Kalathingathodika Sajeer2, Chakanalil Govindan Sajeev3, Cicy Bastian4, Desabandhu Vinayakumar4, Kader Muneer5, Vellani Haridasan6, Dolly Mathew6, Biju George7, Mangalath Narayanan Krishnan8. 1. Additional Professor, Department of Cardiology, Government Medical College, Kozhikode, Kerala 673008, India. Electronic address: drrajeshgnair@gmail.com. 2. Senior Resident, Department of Cardiology, Government Medical College, Kozhikode, Kerala 673008, India. 3. Professor, Additional Professor, Department of Cardiology, Government Medical College, Kozhikode, Kerala 673008, India. 4. Additional Professor, Department of Cardiology, Government Medical College, Kozhikode, Kerala 673008, India. 5. Associate Professor, Department of Cardiology, Government Medical College, Kozhikode, Kerala 673008, India. 6. Assistant Professor, Department of Cardiology, Government Medical College, Kozhikode, Kerala 673008, India. 7. Assistant Professor, Department of Community Medicine, Government Medical College, Kozhikode, Kerala, India. 8. Professor & Head, Department of Cardiology, Government Medical College, Kozhikode, Kerala 673008, India.
Abstract
BACKGROUND: Beta-blockers are frequently used in patients with mitral stenosis to control the heart rate and alleviate exercise-related symptoms. The objective of our study was to examine whether ivabradine was superior to atenolol for achieving higher exercise capacity in patients with moderate mitral stenosis in sinus rhythm. We also evaluated their effects on left ventricular myocardial performance index (MPI). METHODS AND RESULTS:Eighty-two patients with moderate mitral stenosis in sinus rhythm were randomized to receive ivabradine (n=42) 5mg twice daily or atenolol (n=40) 50mg daily for 6 weeks. Transthoracic echocardiography and treadmill test were performed at baseline and after completion of 6 weeks of treatment. Mean total exercise duration in seconds markedly improved in both study groups at 6 weeks (298.57±99.05s vs. 349.12±103.53s; p=0.0001 in ivabradine group, 290.90±92.42s vs. 339.90±99.84s; p=0.0001 in atenolol group). On head-to-head comparison, there was no significant change in improvement of exercise time between ivabradine and atenolol group (p=0.847). Left ventricular MPI did not show any significant change from baseline and at 6 weeks in both drug groups (49.8%±8% vs. 48.3%±7% in ivabradine group, 52.9%±10% vs. 50.9%±10% in atenolol groups; p=0.602). CONCLUSION:Ivabradine or atenolol can be used for heart rate control in patients with moderate mitral stenosis in sinus rhythm. Ivabradine is not superior to atenolol for controlling heart rate or exercise capacity. Left ventricular MPI was unaffected by either of the drugs.
RCT Entities:
BACKGROUND: Beta-blockers are frequently used in patients with mitral stenosis to control the heart rate and alleviate exercise-related symptoms. The objective of our study was to examine whether ivabradine was superior to atenolol for achieving higher exercise capacity in patients with moderate mitral stenosis in sinus rhythm. We also evaluated their effects on left ventricular myocardial performance index (MPI). METHODS AND RESULTS: Eighty-two patients with moderate mitral stenosis in sinus rhythm were randomized to receive ivabradine (n=42) 5mg twice daily or atenolol (n=40) 50mg daily for 6 weeks. Transthoracic echocardiography and treadmill test were performed at baseline and after completion of 6 weeks of treatment. Mean total exercise duration in seconds markedly improved in both study groups at 6 weeks (298.57±99.05s vs. 349.12±103.53s; p=0.0001 in ivabradine group, 290.90±92.42s vs. 339.90±99.84s; p=0.0001 in atenolol group). On head-to-head comparison, there was no significant change in improvement of exercise time between ivabradine and atenolol group (p=0.847). Left ventricular MPI did not show any significant change from baseline and at 6 weeks in both drug groups (49.8%±8% vs. 48.3%±7% in ivabradine group, 52.9%±10% vs. 50.9%±10% in atenolol groups; p=0.602). CONCLUSION:Ivabradine or atenolol can be used for heart rate control in patients with moderate mitral stenosis in sinus rhythm. Ivabradine is not superior to atenolol for controlling heart rate or exercise capacity. Left ventricular MPI was unaffected by either of the drugs.
Authors: J V Monmeneu Menadas; F Marín Ortuño; F Reyes Gomis; A Jordán Torrent; M García Martínez; V Bodí Peris; E García de Burgos de Rico Journal: J Heart Valve Dis Date: 2002-03
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Robert O Bonow; Blase A Carabello; Kanu Chatterjee; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce Whitney Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel Journal: J Am Coll Cardiol Date: 2006-08-01 Impact factor: 24.094
Authors: R Kumar; R K Saran; S K Dwivedi; V S Narain; V K Puri; M Hasan; N Chandra; A Agrawal; N Sinha; R C Ahuja Journal: Indian Heart J Date: 1994 Nov-Dec
Authors: H M Mardikar; V S Sahasrabhojaney; P D Jalgaonkar; U M Mahorkar; M H Mardikar; B G Waghmare Journal: Indian J Med Res Date: 1995-01 Impact factor: 2.375
Authors: John Daniel A Ramos; Elleen L Cunanan; Lauro L Abrahan; Marc Denver A Tiongson; Felix Eduardo R Punzalan Journal: Cardiol Res Date: 2018-08-10